These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26478817)

  • 1. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.
    Cox MM; Izikson R; Post P; Dunkle L
    Ther Adv Vaccines; 2015 Jul; 3(4):97-108. PubMed ID: 26478817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.
    Yang LP
    Drugs; 2013 Aug; 73(12):1357-66. PubMed ID: 23928902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
    Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M
    Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process.
    Buckland B; Boulanger R; Fino M; Srivastava I; Holtz K; Khramtsov N; McPherson C; Meghrous J; Kubera P; Cox MM
    Vaccine; 2014 Sep; 32(42):5496-502. PubMed ID: 25131727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FluBlok, a recombinant hemagglutinin influenza vaccine.
    Cox MM; Patriarca PA; Treanor J
    Influenza Other Respir Viruses; 2008 Nov; 2(6):211-9. PubMed ID: 19453397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.
    Izikson R; Leffell DJ; Bock SA; Patriarca PA; Post P; Dunkle LM; Cox MM
    Vaccine; 2015 Nov; 33(48):6622-8. PubMed ID: 26529070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.
    Henry C; Palm AE; Utset HA; Huang M; Ho IY; Zheng NY; Fitzgerald T; Neu KE; Chen YQ; Krammer F; Treanor JJ; Sant AJ; Topham DJ; Wilson PC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31434733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
    Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL
    BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
    Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
    J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FluBlok, a recombinant influenza vaccine.
    Huber VC; McCullers JA
    Curr Opin Mol Ther; 2008 Feb; 10(1):75-85. PubMed ID: 18228185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ
    J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.
    Jackson LA; Gaglani MJ; Keyserling HL; Balser J; Bouveret N; Fries L; Treanor JJ
    BMC Infect Dis; 2010 Mar; 10():71. PubMed ID: 20236548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.
    Ledgerwood JE; Hu Z; Costner P; Yamshchikov G; Enama ME; Plummer S; Hendel CS; Holman L; Larkin B; Gordon I; Bailer RT; Poretz DM; Sarwar U; Kabadi A; Koup R; Mascola JR; Graham BS;
    Contemp Clin Trials; 2015 Sep; 44():112-118. PubMed ID: 26275339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
    Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
    Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
    [No Abstract]   [Full Text] [Related]  

  • 20. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.